NEW ZEALAND DATA SHEET

1. PRODUCT NAME

RABIPUR Inactivated Rabies Virus Vaccine

Powder and solvent for solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

RABIPUR is an inactivated rabies virus vaccine, derived from the fixed-virus strain, Flury LEP. The virus is propagated in a Purified Chick Embryo Cell (PCEC) culture, inactivated using β-propiolactone and purified via centrifugation. It is supplied in a single-dose presentation consisting of a vial containing lyophilised powder (vaccine component), accompanied by a diluent (Water for Injections).

Each 1.0 mL dose of the reconstituted vaccine contains no less than 2.5 International Units (IU) of inactivated rabies virus, in accordance with the World Health Organization requirements.

This vaccine contains residues of polygeline, chicken proteins (e.g., ovalbumin) and human serum albumin. The antibiotics neomycin, chlortetracycline and amphotericin B (amphotericin) are used in the manufacturing process of this vaccine and may be present in trace amounts.

The manufacture of this product includes exposure to bovine derived materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalitis) has resulted from the administration of any vaccine product.

For the full list of excipients, see section 6.1 List of excipients.

3. PHARMACEUTICAL FORM

Powder and solvent for solution for injection.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

For active immunisation against rabies virus in individuals of all ages, including:

a) Pre-exposure immunisation,

b) Post-exposure treatment following exposure to rabies virus.

4.2 Dose and method of administration

Dose

Recommended dosages, as outlined below, are the same for children, adolescents and adults.

Administration

The vaccine must be given by intramuscular injection (IM) into the deltoid muscle, or into
the anterolateral region of the thigh in small children. The vaccine must not be given by intragluteal injection.

For instructions on reconstitution of the medicine before administration, see section 6.6 Special precautions for disposal and other handling.

*Pre-exposure Prophylaxis*

*Primary immunisation*

In previously unvaccinated persons, an initial course of pre-exposure prophylaxis consists of three doses (each of 1.0 mL) administered on days 0, 7 and 21 or 28.

*Booster doses*

In persons with ongoing risk of exposure to rabies virus, the following general guidance is provided:

- Testing for neutralising antibodies by the Rapid Focus-Fluorescent Inhibition Test (RFFIT) at 6-month intervals is usually recommended if the risk of exposure to rabies virus is high (e.g. Laboratory staff working with rabies virus).
- In persons who are considered to be at continuing risk of exposure to rabies (e.g. veterinarians and their assistants, wildlife workers, hunters), a serological test should usually be performed at least every 2 years, with shorter intervals if appropriate to the perceived degree of risk.
- In above mentioned cases, a booster dose should be given should the antibody titre fall below 0.5 IU/mL.
- Alternatively, in persons with ongoing risk of rabies exposure, booster doses may be offered every 2 to 5 years without serological testing.

RABIPUR may be used for booster vaccination after prior immunisation with human diploid cell rabies vaccine.

*Post-exposure treatment*

Post-exposure immunisation should begin as soon as possible after exposure and should be accompanied by local measures to the site of inoculation so as to reduce the risk of infection.

*Immediate wound treatment*

In order to remove as much of the rabies virus as possible, immediately cleanse the wound with soap and flush thoroughly with water. Then treat with alcohol (70 %) or an iodine tincture. Where possible, bite injuries should not be closed with a suture, or only sutured to secure apposition. Prophylaxis against tetanus should be administered when necessary.

In cases where passive immunisation is also indicated, as much of the recommended dose of HRIG as is anatomically feasible should be applied as deeply as possible in and around the wound. Any remaining HRIG should be injected intramuscularly at a site distant from the site of vaccine administration (preferably intragluteally).

*Previously fully immunised individuals*

For WHO exposure categories II and III, and in category I cases where there is uncertainty regarding the correct classification of exposure (see Table 6 below), two doses (each of
1.0 mL) should be administered on both day 0 and day 3. On a case by case basis, schedule A (see Table 7 below) may be applied if the last dose of vaccine was given more than two years previously.

### Table 1: Immunisation schedules appropriate to different types of exposure
(Published by World Health Organization, 2002)

<table>
<thead>
<tr>
<th>Exposure Category</th>
<th>Type of contact with suspect or confirmed rabid domestic or wild animal, or animal unavailable for observation(^{\text{a}})</th>
<th>Recommended treatment</th>
</tr>
</thead>
</table>
| I                 | Touching or feeding of animals
Licks on intact skin
Touching of inoculated animal lure with intact skin | None, if reliable case history is available.
In case of unreliable case history, treat according to schedule A (see Table 2). |
| II                | Nibbling of uncovered skin
Minor scratches or abrasions without bleeding
Licks on broken skin
Touching of inoculated animal lure with damaged skin | Administer vaccine immediately \(^{\text{b}}\) as in schedule A (see Table 2). In case of uncertainty and/or exposure in a high-risk area, administer active and passive treatment as in schedule B (see Table 2).
(See also footnote \(^{\text{c}}\)) |
| III               | Single or multiple transdermal bites or scratches
Contamination of mucous membrane with saliva (i.e. licks)
Touching of inoculated animal lure with mucous membrane or fresh skin wound | Administer rabies immunoglobulin and vaccine immediately \(^{\text{b}}\) as in schedule B (see Table 2).
(See also footnote \(^{\text{d}}\)) |

\(^{\text{a}}\) Exposure to rodents, rabbits and hares seldom, if ever, requires specific anti-rabies treatment.

\(^{\text{b}}\) If an apparently healthy dog or cat in or from a low-risk area is placed under observation, it may be justified to delay specific treatment.

\(^{\text{c}}\) Stop treatment if animal is a cat or dog and remains healthy throughout an observation period of 10 days or if animal is euthanised and found to be negative for rabies by appropriate laboratory techniques. Except in the case of threatened or endangered species, other domestic and wild animals suspected as rabid should be euthanised and their tissues examined using appropriate laboratory techniques.

### Individuals non-immunised or with uncertain immune status

Depending on the WHO category as in Table 1, treatment according to schedules A or B (see Table 2 below) may be required for previously non-immunised persons and for those who have received fewer than 3 doses of vaccine or who have received a vaccine of doubtful potency.

### Table 2: Post-exposure treatment of subjects with no or uncertain immune status

<table>
<thead>
<tr>
<th>Schedule A</th>
<th>Schedule B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active immunisation after exposure is required</td>
<td>Active and passive immunisation after exposure are required</td>
</tr>
</tbody>
</table>
One injection of RABIPUR i.m. on days: 0, 3, 7, 14, 28 (5-doses schedule)

Or

One dose of RABIPUR is given into the right deltoid muscle and one dose into the left deltoid muscle on day 0, and one dose is applied into the deltoid muscle on days 7 and 21 (2-1-1 regimen). In small children the vaccine is to be given into the thighs.

Administer RABIPUR as in schedule A + 1 x 20 IU/kg body weight human rabies immunoglobulin* concomitantly with the first dose of RABIPUR. If HRIG is not available at the time of the first vaccination it must be administered not later than 7 days after the first vaccination.

* Observe manufacturer's instructions regarding administration

**Immunocompromised patients and patients with a particularly high risk of contracting rabies**

For immunocompromised patients, those with multiple wounds and/or wounds on the head or other highly innervated areas, and those for whom there is a delay before initiation of treatment, it is recommended that:

- The days 0, 3, 7, 14 and 28 immunisation regimen should be used for these cases
- Two doses of vaccine may be given on day 0. That is, a single dose of 1.0 mL vaccine should be injected into the right deltoid and another single dose into the left deltoid muscle. In small children, one dose should be given into the anterolateral region of each thigh.

Severely immunosuppressed patients may not develop an immunologic response after rabies vaccination. Therefore, prompt and appropriate wound care after exposure is an essential step in preventing death. In addition, rabies immunoglobulin should be administered in all immunosuppressed patients experiencing Category II and Category III wounds.

For immunocompromised patients, the neutralising antibody titre should be measured 14 days after the first injection. Patients with a titre that is less than 0.5 IU/mL should be given another two doses of vaccine simultaneously as soon as possible. Further checks on the antibody titre should be made and further doses of vaccine should be administered as necessary.

### 4.3 Contraindications

a) Pre-exposure immunisation

RABIPUR is contraindicated in subjects with a known severe hypersensitivity to any of the components of the vaccine, including chicken eggs, chicken protein, bovine gelatin, neomycin, chlorotetracycline and amphotericin B (amphotericin).

Vaccination should be delayed in subjects suffering from an acute febrile illness. Minor infections are not a contraindication to vaccination.

b) Post-exposure treatment

In view of the fatal outcome of clinically manifest rabies, any suspicion of infection should always lead to treatment. Subjects that have a severe hypersensitivity to components of the vaccine should not receive the vaccine for post-exposure treatment unless a suitable
alternative vaccine is not available, in which case all injections should be administered with close monitoring and with facilities for emergency treatment available.

### 4.4 Special warnings and precautions for use

**For intramuscular injection only.**

Serious systemic anaphylactic reactions, including cases of anaphylactic shock, have been reported in temporal association with RABIPUR.

Serious neurological events, such as encephalitis, Guillain-Barré-Syndrome, meningitis, multiple sclerosis, myelitis, paresis, and retrobulbar neuritis have been reported (<1:100,000) in temporal association with RABIPUR.

If complications arise following any of the series of injections in the schedule, do not continue with further vaccine doses until the cause of the complications have been clarified.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.

In patients with known hypersensitivity to constituents of the vaccine receiving post-exposure treatment, appropriate remedial facilities for treating anaphylactic shock should always be available during immunisation, or alternatively another equivalent modern cell culture rabies vaccine should be used.

A history of allergy to eggs or a positive skin test to ovalbumin does not necessarily indicate that a subject will be allergic to RABIPUR. However, subjects who have a history of a severe hypersensitivity reaction to eggs or egg products should not receive the vaccine for pre-exposure prophylaxis.

Patients who are immunocompromised, including those receiving immunosuppressive therapy or high dose corticosteroids, may not mount an adequate response to rabies vaccine. Therefore, it is recommended that serological responses should be monitored in such patients and additional doses given as necessary.

Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions, may occur in association with vaccination as a psychogenic response to the needle injection. (see Adverse reactions) It is important that procedures are in place to avoid injury from fainting

RABIPUR may contain residual amounts of the antibiotics neomycin, chlortetracycline and amphotericin B (amphotericin).

Do not inject intravascularly. Unintentional intravascular injection may result in systemic reactions, including shock.

Rabies vaccine must not be given by intra-gluteal injection or subcutaneously, as the induction of an adequate immune response may be less reliable. Do not administer the vaccine intradermally.

The vaccine must not be mixed in the same syringe with other medicinal products. If rabies immunoglobulin is indicated in addition to Rabipur vaccine, then it must be administered at an anatomical site distant to the vaccination (see 4.5INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS).
Adherence to treatment guidelines, as outlined below, are of utmost importance in order to minimise risk of rabies disease. However, in very few cases development of rabies disease despite correct treatment has been reported. Direct inoculation of the rabies virus into nerve endings has been discussed as an explanation for these rare cases.

As with other vaccines, a protective immune response may not be achieved in all patients who receive the vaccine.

### 4.5 Interaction with other medicines and other forms of interaction

Other vaccines, which are deemed clinically essential, may be given at the same time as RABIPUR. Different injectable vaccines should be administered into separate injection sites.

For patients receiving immunosuppressive therapy, or with congenital or acquired immunodeficiency, the response to the vaccination may be reduced or absent. Therefore, it is recommended that serological responses should be monitored in such subjects, and additional doses administered as necessary.

Immunosuppressive therapy during post-exposure treatment should be avoided. Anti-rabies immunoglobulins may attenuate the effects of concomitantly administered rabies vaccine. All of the rabies immunoglobulin, or as much as anatomically possible (but avoiding possible compartment syndrome), should be administered into or around the wound site or sites. The remaining immunoglobulin, if any, should be injected intramuscularly at a site distant from the site of vaccine administration to avoid possible interference with simultaneously administered rabies vaccine.

### 4.6 Fertility, pregnancy and lactation

**Pregnancy**

Animal embryofetal development studies have not been conducted with the vaccine. It is not known whether the vaccine can cause fetal harm when administered to a pregnant woman or can effect reproductive capacity. For pre-exposure vaccination, RABIPUR should not be given to a pregnant woman, unless benefits outweigh potential risks and vaccination is clearly needed, as might occur in high risk situations.

Pregnancy is never a contraindication to post-exposure rabies vaccination. In post-exposure situations the vaccine should be given as recommended.

No cases of harm attributable to use of this vaccine during pregnancy have been observed in mothers or children.

**Lactation**

It is not known whether RABIPUR is excreted in human milk. Caution should be exercised when the vaccine is administered to a nursing mother.

It is advisable to carefully weigh expected benefits against potential risks prior to prophylactic administration of RABIPUR during lactation.

**Fertility**

Reproductive toxicity studies have been performed with RABIPUR.

### 4.7 Effects on ability to drive and use machines

No studies have been carried out with Rabipur to assess the effect on the ability to drive or
use machines. 4.8 Undesirable effects

As with all vaccines and as outlined below, RABIPUR administration may cause unintended reactions. However, not all events occurring after vaccination are causally related to the vaccine. For any unexpected effects while taking RABIPUR, contact your physician or pharmacist.

Adverse Drug Reaction Overview

In very rare cases, neurological and neuropsychiatric events and cases of hypersensitivity have been reported in temporal association with administration of RABIPUR.

The most commonly occurring adverse reactions are injection-site reactions, such as injection-site erythema, induration and pain; flu-like symptoms, such as asthenia, fatigue, fever, headache, myalgia and malaise; arthralgia, dizziness, lymphadenopathy, nausea, and rash.

A patient’s risk of acquiring rabies must be carefully considered before deciding to discontinue vaccination.

Clinical Trials Experience

As clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to vaccine use and for approximating rates.

In a comparative trial in normal volunteers, Dreesen et al (Vaccine. 1989;7:397-400) described their experience with RABIPUR compared to a human diploid cell culture rabies vaccine (HDCV). Nineteen subjects received RABIPUR and 20 received HDCV. The most commonly reported adverse reaction was pain at the injection site, reported in 45% of the HDCV group, and 34% of the RABIPUR group. Localised lymphadenopathy was reported in about 15% of each group. The most common systemic reactions were malaise (15% RABIPUR group versus 25% HDCV group), headache (10% RABIPUR group versus 20% HDCV group), and dizziness (15% RABIPUR group versus 10% HDCV group).

In a recent study in the USA, 83 subjects received RABIPUR and 82 received HDCV. Again, the most common adverse reaction was pain at the injection site in 80% in the HDCV group and 84% in the RABIPUR group. The most common systemic reactions were headache (52% RABIPUR group versus 45% HDCV group), myalgia (53% RABIPUR group versus 38% HDCV group) and malaise (20% RABIPUR group versus 17% HDCV group). None of the adverse events were serious, almost all adverse events were of mild or moderate intensity.
Other common adverse events reported in clinical trials

The data from clinical trials described below reflect exposure to RABIPUR in 1307 subjects, including 355 subjects in pre-exposure vaccination settings and 952 patients, who received RABIPUR for post-exposure prophylaxis. RABIPUR was studied primarily in single-blind, randomised controlled trials. The population studied was mainly Caucasian and Asian, ranging from healthy infants to healthy adults with an equal gender distribution. Patients only received intramuscular administration of RABIPUR.

<table>
<thead>
<tr>
<th>Body System</th>
<th>Frequency</th>
<th>Adverse Reactions (Clinical Trials, n=1307)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General disorders and administration-site condition</td>
<td>Very common (≥1/10)</td>
<td>Injection-site reaction, injection-site Induration, Asthenia, fever, fatigue</td>
</tr>
<tr>
<td></td>
<td>Common (≥1/100 and &lt;1/10)</td>
<td>Influenza-like illness, injection-site erythema</td>
</tr>
<tr>
<td></td>
<td>Rare ≥1/10,000 and &lt;1/1,000</td>
<td>Chills</td>
</tr>
<tr>
<td>Skin and subcutaneous disorders</td>
<td>Very common (≥1/10)</td>
<td>Rash</td>
</tr>
<tr>
<td></td>
<td>Common (≥1/100 and &lt;1/10)</td>
<td>Urticaria</td>
</tr>
<tr>
<td></td>
<td>Rare ≥1/10,000 and &lt;1/1,000</td>
<td>Hyperhidrosis</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Common (≥1/100 and &lt;1/10)</td>
<td>Arthralgia, Myalgia</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Common (≥1/100 and &lt;1/10)</td>
<td>Gastrointestinal disorders (such as nausea, vomiting, diarrhoea or abdominal pain/discomfort)</td>
</tr>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td>Common (≥1/100 and &lt;1/10)</td>
<td>Decreased appetite</td>
</tr>
<tr>
<td>Immune System Disorders</td>
<td>Rare ≥1/10,000 and &lt;1/1,000</td>
<td>Hypersensitivity</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Common</td>
<td>Lymphadenopathy</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td>Very common</td>
<td>Headache, Dizziness</td>
</tr>
<tr>
<td></td>
<td>Rare ≥1/10,000 and &lt;1/1,000</td>
<td>Paraesthesia</td>
</tr>
</tbody>
</table>
Post-Marketing Adverse Drug Reactions

Those adverse reactions identified during post-approval use of RABIPUR can be found in the following table. As these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. Decisions to include these reactions in labelling are typically based on one or more of the following factors: 1) seriousness of the reaction, 2) frequency of reporting, or 3) strength of causal connection to vaccine exposure, or a combination of these factors.

Adverse reactions information (post-marketing)

<table>
<thead>
<tr>
<th>Body System</th>
<th>Adverse Reactions (only observed in post-approval use, n ≥ 10,000,000); frequency &lt; 1 : 1,000 for all events</th>
</tr>
</thead>
<tbody>
<tr>
<td>General disorders and administration-site condition</td>
<td>Chills, sweating</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Circulatory reactions (such as palpitations or hot flush)</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>Vertigo</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Visual disturbance</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Paraesthesia</td>
</tr>
<tr>
<td></td>
<td>Nervous system disorders (such as encephalitis, paresis or Guillain-Barré-Syndrome), presyncope, syncope</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Allergic reactions (such as anaphylaxis including anaphylactic shock, bronchospasm, oedema, pruritus, rash or urticaria)</td>
</tr>
<tr>
<td></td>
<td>Type III hypersensitivity-like symptoms</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Pain in limbs, limb swelling</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Angioedema</td>
</tr>
</tbody>
</table>

Once initiated, rabies prophylaxis should not be interrupted or discontinued because of local or mild systemic adverse reactions to rabies vaccine. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents.

In post-marketing experience to November 2004 (a period in which approximately 33 million doses have been distributed) 47 deaths due to rabies were reported in persons who had been received post-exposure treatment with RABIPUR. In all but three cases WHO recommendations for post-exposure treatment had not been followed. The other three cases involved severe exposures such as facial bites.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It
allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via: https://nzphvc.otago.ac.nz/reporting

4.9 Overdose

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

ATC code: J07B G01

Injection of the vaccine induces production of an antibody titre that markedly exceeds 0.5 IU/mL of serum, the threshold considered to provide adequate protection. As the antibody concentration slowly falls, booster doses are required to maintain antibody levels above the acceptable level of 0.5 IU/mL.

Clinical trials

Pre-exposure Immunisation

The immunogenicity of RABIPUR has been demonstrated in clinical trials conducted in Europe, North America and Asia. When administered according to the recommended immunisation schedule (days 0, 7, 21 or 28), 100% of subjects attained an adequate titre of 0.5 IU/mL by day 28 or earlier. Persistence of antibody titres ≥ 0.5 IU/mL for up to 2 years after immunisation with RABIPUR has been measured in clinical trials.

Table 5 details the serum antibody titres of subjects, vaccinated according to the pre-exposure vaccination dosage regimen with either RABIPUR or Human Diploid Cell rabies Vaccine (HDCV). These data demonstrate that RABIPUR causes production of antibodies, with geometric mean titres (GMT) greater than 0.5 IU/mL by Day 28. The study also demonstrated no statistically significant difference in GMT following vaccination with either type of vaccine.

Table 5. Antibody titres following pre-exposure vaccination with RABIPUR and HDCV

<table>
<thead>
<tr>
<th>Day</th>
<th>Rabies Antibody conc (IU/mL)</th>
<th>RABIPUR (n=82)</th>
<th>HDCV (n=79)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>GMT Range</td>
<td>0.25 (0.25 – 0.25)</td>
<td>0.25 (0.25 – 0.25)</td>
</tr>
<tr>
<td>28</td>
<td>GMT Range</td>
<td>9.3 (0.8 – 68.0)</td>
<td>12.0 (2.0 – 95.0)</td>
</tr>
<tr>
<td>49</td>
<td>GMT Range</td>
<td>25.3 (3.0 – 70.0)</td>
<td>25.8 (4.0 – 120.0)</td>
</tr>
</tbody>
</table>

In other studies, long term antibody titres following pre-exposure vaccination with RABIPUR were evaluated in 36 patients. The study showed that 2 years post-vaccination, the antibody GMTs remained above 0.5 IU/mL for 64% of recipients vaccinated. Antibody titre data is provided in Table 6.
Table 6. Long term antibody titres following vaccination with RABIPUR

<table>
<thead>
<tr>
<th></th>
<th>Day 0 (n=36)</th>
<th>Day 28 (n=36)</th>
<th>Day 48 (n=36)</th>
<th>Day 90 (n=34)</th>
<th>Year 2 (n=28)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum Titre (IU/mL)</td>
<td>&lt;0.02</td>
<td>0.58</td>
<td>4.48</td>
<td>0.90</td>
<td>0.05</td>
</tr>
<tr>
<td>Geometric Mean Titre (GMT) (IU/mL)</td>
<td>&lt;0.02</td>
<td>2.47</td>
<td>12.73</td>
<td>5.06</td>
<td>0.80</td>
</tr>
<tr>
<td>No. of subjects with titre ≥0.5 IU/mL</td>
<td>0</td>
<td>36</td>
<td>36</td>
<td>34</td>
<td>18</td>
</tr>
<tr>
<td>% of subjects with GMT ≥0.5 IU/mL</td>
<td>0</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td>64</td>
</tr>
</tbody>
</table>

Post-exposure Immunisation

Clinical studies in patients exposed to rabies virus have demonstrated that RABIPUR, when used in the recommended post-exposure WHO schedule of 5 x 1.0 mL Intramuscular injections (on days 0, 3, 7, 14, 28), provided protective titres of neutralising antibodies (>0.5 IU/mL) in 98% of patients within 14 days and in 100% of patients by day 30. Similar results were obtained in several studies with healthy volunteers who had been given the WHO recommended post-exposure regimen ("simulated" post-exposure immunisation). Table 7 details the proportion of subjects who developed a protective antibody titre (≥0.5 IU/mL) following vaccination in accordance with the post-exposure regimen.

Table 7. Proportion of subjects achieving a protective antibody titre following post-exposure vaccination with RABIPUR

<table>
<thead>
<tr>
<th>Day</th>
<th>No of subjects with GMT ≥0.5 IU/mL (n=37)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>11 / 37 (29.7%)</td>
</tr>
<tr>
<td>14</td>
<td>35 / 37 (94.6%)</td>
</tr>
<tr>
<td>30</td>
<td>36 / 36 (100.0%)</td>
</tr>
<tr>
<td>90</td>
<td>36 / 36 (100.0%)</td>
</tr>
<tr>
<td>365</td>
<td>33 / 34 (97.1%)</td>
</tr>
</tbody>
</table>

One study followed cohorts of patients presenting with bites from laboratory proven rabid animals for one year. No case of rabies was observed in this patient population. Some patients received passive immunisation with Human Rabies Immunoglobulin (HRIG) 20 - 30 IU/kg body weight, or Equine Rabies Immune Globulin (ERIG), 40 IU/kg body weight, at the time of the first vaccine dose. Analysis of the data concluded that the addition of either HRIG or ERIG caused a slight decrease in GMTs when compared to subjects not receiving the immunoglobulin; this slight decrease was deemed neither clinically relevant nor statistically significant.

Booster Immunisation

The ability of RABIPUR to boost antibody titres in previously immunised subjects has been examined through clinical studies. Data from one study demonstrated that after one booster dose, a 10-fold or higher increase in GMTs on day 30 were observed in subjects previously vaccinated with HDCV. A significant increase was observed among all vaccinees with antibody titres of >0.5 IU/mL at baseline on day 0. Table 8 details the GMT’s for this trial.
Table 8. Antibody titres following booster immunisation with RABIPUR

<table>
<thead>
<tr>
<th></th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Group D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median GMT (IU/mL) –</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 0</td>
<td>1.50</td>
<td>0.40</td>
<td>2.20</td>
<td>1.57</td>
</tr>
<tr>
<td>Day 28</td>
<td>15.05</td>
<td>11.00</td>
<td>6.85</td>
<td>14.20</td>
</tr>
</tbody>
</table>

Group A – Pre-exposure immunisation with HDCV <1 year prior to study
Group B – Pre-exposure immunisation with HDCV <2 years prior to study
Group C – Pre-exposure immunisation with HDCV <5 years prior to study
Group D – Post-exposure immunisation with HDCV <1 year prior to study

Data from an additional booster vaccination study demonstrated that individuals known to have been previously immunised with a PCEC vaccine or Human Diploid Cell Vaccine (HDCV), developed a rapid anamnestic response when boosted with RABIPUR. A booster response was observed on day 7 for all individuals. One RABIPUR intramuscular booster dose resulted in a significant increase in antibody titers in all subjects, regardless of whether they had received RABIPUR or HDCV as the primary vaccine. More than one year after primary immunisation, one or two IM doses of RABIPUR induced a 10-fold or higher increase in GMTs by day 7. On day 21 post-booster, the GMTs of subjects that received two booster doses of vaccine were higher than those that received one booster dose of vaccine.

Table 9. Antibody titre data following one or two booster doses of RABIPUR

<table>
<thead>
<tr>
<th>Day</th>
<th>Geometric Mean Titre</th>
<th>RABIPUR Booster Day 0</th>
<th>RABIPUR Booster Days 0, 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>-3</td>
<td></td>
<td>n</td>
<td>Rabies Ab (IU/mL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>69</td>
<td>2.33</td>
</tr>
<tr>
<td>3</td>
<td>Geometric Mean Titre</td>
<td>69</td>
<td>2.87</td>
</tr>
<tr>
<td>7</td>
<td>Geometric Mean Titre</td>
<td>69</td>
<td>51.23</td>
</tr>
<tr>
<td>21</td>
<td>Geometric Mean Titre</td>
<td>68</td>
<td>120.91</td>
</tr>
</tbody>
</table>

5.2 Pharmacokinetic properties

Not applicable

5.3 Preclinical safety data

No carcinogenicity, genotoxicity or reproductive toxicity studies have been performed with RABIPUR.

6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients

Each 1.0 mL dose of the reconstituted vaccine also contains the following excipients: trometamol (3.5 mg), sodium chloride (4.5 mg), disodium edetate (0.25 mg), monopotassium glutamate (0.9 mg), polygeline (10.5 mg), sucrose (60 mg) and Water for Injections (1.0 mL). The quantities of each excipient (excluding Water for Injection) will vary dependent on virus concentration in the harvested material.

6.2 Incompatibilities

Do not mix vaccines within the same syringe.

6.3 Shelf life

48 months

6.4 Special precautions for storage

Store vaccine at 2°C - 8°C (in a refrigerator). Do not freeze. Store diluent below 25°C.

Contains no antimicrobial agent. Product is for single use in one patient only.

6.5 Nature and contents of container

RABIPUR is available in the following pack sizes:

- 1 single dose lyophilised vaccine vial (type 1 glass) with a stopper (chlorobutyl), with 1 single dose disposable pre-filled syringe (type 1 glass) with a plunger-stopper (bromobutyl) containing diluent (1.0 mL), without needle and with a tip-cap (bromobutyl).

Not all presentations may be marketed.

6.6 Special precautions for disposal and other handling

Reconstitution

The vaccine should be visually inspected both before and after reconstitution for any foreign particulate matter and/or change in physical appearance. The vaccine must not be used if any change in the appearance of the vaccine has taken place.

The powder for solution should be reconstituted by addition of the diluent supplied using a sterile syringe. The reconstituted vaccine must be carefully agitated to avoid foaming prior to injection and should be used immediately with any unused vaccine or waste material suitably disposed.

The reconstituted vaccine is clear to slightly opalescent and colourless to slightly pink.

The vial of vaccine contains negative pressure. After reconstitution of the vaccine, it is recommended to unscrew the syringe from the needle to eliminate the negative pressure. After that, the vaccine can be easily withdrawn from the vial. It is not recommended to induce excess pressure, since over-pressurization will create the problems in withdrawing the proper amount of the vaccine.

Specific instructions for preparation of the presentation containing the diluent in a pre-filled syringe are provided below.
Instructions for use and handling

Administration of RABIPUR presented in a pre-filled syringe.

Step 1: With one hand, hold the syringe (E) with the cap pointing upward. Be sure to hold the syringe by the white textured holding ring (D).

Step 2: With the other hand, grasp the cap (A) and firmly rock it back and forth to break its connection to the holding ring (D). **Do not twist or turn the cap.**

Step 3: Lift up to remove the cap (A) and the attached gray tip cap (B). Be careful not to touch the sterile syringe tip (C).

Instructions for attaching needle

To attach a reconstitution needle, firmly hold the syringe (E) with one hand by the white textured holding ring (D). With your other hand, insert needle and twist clockwise until it locks into place. Once needle is locked, remove its plastic cover.

The syringe (E) is now ready for use.

After completing the reconstitution of the vaccine, replace the reconstitution needle with an administration needle.

7. **MEDICINE SCHEDULE**

Prescription Medicine
8. **SPONSOR**

Seqirus (NZ) Ltd  
PO Box 62 590  
Greenlane, Auckland 1546  
New Zealand  
Telephone: 0800 502 757

9. **DATE OF FIRST APPROVAL**

Date of publication in the New Zealand Gazette of consent to distribute the medicine:  
26 February 2015

10. **DATE OF REVISION OF THE TEXT**

25 March 2021

Summary table of changes:

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Included reference to diluent</td>
</tr>
<tr>
<td>4.2</td>
<td>Updated administration instructions, including reference to diluent</td>
</tr>
<tr>
<td>4.2</td>
<td>Corrected HRIG dose to 1 x 20 IU</td>
</tr>
<tr>
<td>4.4</td>
<td>Aligned vaccine protection text with AU Product Information</td>
</tr>
<tr>
<td>4.5</td>
<td>Text aligned with Global Data Sheet</td>
</tr>
<tr>
<td>4.7</td>
<td>Text aligned with Global Data Sheet</td>
</tr>
<tr>
<td>4.8</td>
<td>Tables aligned with Global Data Sheet</td>
</tr>
<tr>
<td>4.9</td>
<td>Deleted text on overdose symptoms</td>
</tr>
<tr>
<td>6.1</td>
<td>Excipient name changed to monopotassium glutamate</td>
</tr>
<tr>
<td>6.5</td>
<td>Presentations updated</td>
</tr>
<tr>
<td>6.6</td>
<td>Updated handling instructions</td>
</tr>
<tr>
<td>8</td>
<td>Change sponsor to Seqirus</td>
</tr>
</tbody>
</table>

Trademarks are owned by Bavarian Nordic A/S.